failed to show the anticipated beneficial effect on CVD outcomes. As a result, attention has begun to shift toward strategies to improve HDL functionality, rather than levels of HDL-C per se. ApoA-I, the major protein component of HDL, is considered to play an important role in many of the antiatherogenic functions of HDL, most notably reverse cholesterol transport (RCT), and several therapies have been developed to mimic apoA-I function, including administration of apoA-I, mutated variants of apoA-I, and apoA-I mimetic peptides. Based on the potential anti-inflammatory effects, apoA-I mimetics hold promise not only as anti-atherosclerotic therapy but also in other therapeutic areas.
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Introduction
The beneficial consequences of lowering low-density lipoprotein cholesterol (LDL-C) on cardiovascular (CVD) events have been unequivocally shown in numerous intervention studies. A plasma LDL-C reduction of 1.0 mmol/L has been shown to reduce the risk of major cardiovascular events by approximately 20 %, irrespective of baseline cholesterol or risk. Intensive LDL-C lowering is therefore advocated in most guidelines (Baigent et al. 2010) . However, despite the efficiency of established therapies, the residual burden of disease remains substantial (Roger et al. 2012) . Novel targets for therapy are therefore eagerly awaited in order to decrease the residual CVD risk. A large number of epidemiological studies have shown that levels of highdensity lipoprotein cholesterol (HDL-C) are inversely associated with CVD risk. In fact, it has been calculated from these studies that a 1 mg/dL (0.03 mmol/L) increase in HDL-C would translate into a 2-3 % reduction of risk for subsequent coronary events (Gordon et al. 1989) . Moreover, levels of HDL-C have been considered a stronger predictive factor of incident coronary heart disease than levels of LDL-C (Gordon et al. 1977) . Even among patients who attain low levels of LDL-C while receiving LDL-C lowering therapy, levels of HDL-C remain predictive for subsequent CVD events (Barter et al. 2007; Jafri et al. 2010) .
These epidemiological data do not infer a causal relation between levels of HDL-C and CVD risk. However, a number of antiatherogenic mechanisms have been ascribed to HDL. HDL has been shown to play a pivotal role in reverse cholesterol transport (RCT), a pathway by which cholesterol is transported from peripheral cells (e.g., macrophages within the vessel wall) to the liver for biliary excretion (Fielding and Fielding 1995) . In addition, HDL has been shown to possess antioxidant, anti-inflammatory (Barter et al. 2004) , antithrombotic (Mineo et al. 2006) , and antiapoptotic properties (Suc et al. 1997) .
HDL has been considered a target for therapy to lower CVD risk, based on both these epidemiological and biological arguments of atheroprotection. In recent years, a number of large clinical trial programs investigating the efficacy of drugs with an established effect on HDL-C levels have been terminated because of the inability to induce improvement in clinical outcomes. In addition, treatmentinduced changes in HDL-C were not associated with CVD risk after adjusting for LDL-C (Briel et al. 2009 ). Moreover, a number of common genetic variants in genes coding for proteins involved in HDL metabolism have been shown to alter levels of HDL-C without showing the anticipated effect on CVD risk (Haase et al. 2011; Voight et al. 2012) . These findings challenge the concept that levels of circulating HDL-C are causally related to atherosclerosis, and assessment of HDL functionality has therefore been proposed to better reflect the therapeutic potential of therapies targeting HDL (deGoma et al. 2008) .
Although levels of HDL-C alone may thus be a poor target for therapies, apolipoprotein A-1 (apoA-I) itself could in fact represent a promising target. ApoA-I is the major protein component of the HDL particle and considered to play a pivotal role in many of the antiatherogenic properties attributed to HDL. The role of apoA-I in the protection against atherosclerosis has been shown in a number of rodent studies. In low-density lipoprotein receptor (LDL-R) null mice, apoA-I deficiency was shown to result in increased atherosclerosis (Moore et al. 2003) . Increased atherosclerotic lesion development was also seen in apoA-I knockout mice expressing human apolipoprotein B (apoB) when fed a Western diet (WD) (Voyiaziakis et al. 1998) . Additional proof of the antiatherogenic role of apoA-I was derived from animal models of human apoA-I overexpression and in mice treated with apoA-I infusions, in which it was consistently shown that apoA-I provides protection against atherosclerotic lesion formation in proatherogenic animal models (Duverger et al. 1996; Miyazaki et al. 1995; Rubin et al. 1991) . Moreover, mutations in the gene coding for apoA-I have been shown to alter CVD risk in humans. Most of the carriers of mutations in the apoA-I gene are characterized by low levels of HDL-C and an increased risk of CVD (Hovingh et al. 2004) . ApoA-I is widely accepted as an attractive target for therapy based on the consistent data derived in animal and human studies. Several therapies have been developed that mimic apoA-I function, including administration of full length apoA-I, mutated variants of apoA-I, and apoA-I mimetic peptides.
2
ApoA-I Mimetic Peptides
ApoA-I comprises a total of 243 amino acids and its secondary structure resembles 10 amphipathic α-helices that are crucial for its efficient interaction with lipids. Recently, there has been increasing interest in the application of peptides that resemble the amphipathic helices in apoA-I as therapeutic agents. Anantharamaiah et al. synthesized the first apoA-I mimetic peptide, 18A, comprising 18 amino acids. Subsequently, several modifications to 18A have been made to create peptides that more closely mimic apoA-I in its antiatherogenic functions. For example, blocking the ends of 18A with an amide group and an acetyl group, thereby creating a peptide called 2 F, increased its helicity and efficiency in inducing cholesterol efflux (Venkatachalapathi et al. 1993; Yancey et al. 1995) . In addition, tandem peptides composed of more than one amphipathic helix were shown to have a superior lipid affinity and ability to induce cholesterol efflux from macrophages compared to peptides that contain only one helix (Anantharamaiah et al. 1985; Garber et al. 1992; Wool et al. 2008) . D'Souza et al. investigated the effect on cholesterol efflux and anti-inflammatory and antioxidant properties of 22 different bihelical apoA-I mimetic peptides. None of the compounds was superior in all antiatherogenic functions, and each of the examined antiatherogenic functions was shown to be primarily affected by specific structural features . These results indicate that apoA-I mimetic peptides more closely resembling apoA-I do not necessarily improve all various antiatherosclerotic functions. Moreover, combining several apoA-I mimetic peptides, each mimicking different structural aspects of apoA-I, may prove to be a valuable strategy to mimic the various anti-atherosclerotic properties of apoA-I.
4F
Despite potent anti-inflammatory and antioxidant effects in vitro and in experimental models, the promise of 4 F in humans has not been a success to date (Navab et al. 2002 . Two trials of 4 F in patients with CHD or at high risk of CVD assessed the effect of orally and parenterally administered 4 F on the HDL inflammatory index, a measure of HDL-mediated protection against LDL-induced monocyte chemotaxis, providing conflicting results (Bloedon et al. 2008; Watson et al. 2011) . The development of 4 F by Novartis has subsequently been discontinued. Although a number of differences between the studies may partially account for the observed discrepancy, the primary outcome measure "HDL inflammatory index" has been proven to be largely irreproducible in the majority of laboratories. In fact, it has been difficult to identify an efficacy parameter for apoA-I mimetic peptides in human trials altogether, and in lack of standardization, all trials using HDL quality as readout have been disappointing.
6F
A disadvantage of many apoA-I mimetic peptides is that they require end blocking to be effective, which precludes its synthesis by living organisms. Large-scale production of the peptides for therapeutic use would therefore be too expensive.
In a search for apoA-I mimetic peptides that do not require end blocking, 6 F yielded promising results. L-6 F has been shown to possess antioxidant and anti-inflammatory properties in several mice models (Chattopadhyay et al. 2013; Navab et al. 2013) . Given that the small intestine may be an important site of action for apoA-I mimetic peptides, the observed reduction in plasma levels of the proinflammatory and proatherogenic lipid lysophosphatidic acid (LPA) following administration of L-6 F is of particular interest. Feeding LDL-R knockout mice a Western diet does result in changes in intestinal gene expression and proinflammatory and hypercholesterolemic changes in serum. Similar changes were observed when mice were fed unsaturated LPA. Administration of L-6 F reduced intestinal LPA levels and prevented the Western diet-mediated proatherogenic changes in intestinal gene expression. In addition, when L-6 F was administered to mice on chow supplemented with LPA, intestinal levels of unsaturated LPA were significantly reduced, and this decrease correlated with reduced systemic inflammation and hypercholesterolemia (Chattopadhyay et al. 2013; Navab et al. 2013) . Thus, reducing levels of intestinal LPA may be an important mechanism of action for L-6 F.
To enable the large-scale production of the peptide, transgenic, 6 F expressing tomatoes have been developed. Feeding LDL-R knockout mice a Western diet with and without transgenic tomatoes expressing 6 F improved an array of biomarkers of inflammation and antioxidant status and significantly reduced aortic lesion area compared to controls following 13 weeks of treatment (Chattopadhyay et al. 2013 ).
FX-5A
The peptide 5A is synthesized by replacing 5 amino acids of the apoA-I mimetic peptide 37pA with alanine residues, thereby decreasing its lipid affinity. Although 37pA effectively induces cholesterol efflux, its high lipid affinity is associated with cytotoxicity because of adverse effects on the integrity of the plasma membrane (Remaley et al. 2003) . As a result of the amino acid substitutions, 5A is less cytotoxic and induces cholesterol efflux more specifically through ATP-binding cassette transporter A1 (ABCA1) (Sethi et al. 2008) .
The 5A-phospholipid complex has been shown to induce cholesterol efflux both through ABCA1 and ATP-binding cassette transporter G1 (ABCG1). Administration of a single intravenous dose of a 5A-phospholipid complex was shown to enhance reverse cholesterol transport, as evidenced by a flux of cholesterol from peripheral cells to plasma, an increased amount of cholesterol and phospholipids in the HDL fraction, and an enhanced fecal sterol and bile acid secretion (Amar et al. 2010 ). In addition, 5A has been shown to possess anti-inflammatory and antioxidant properties (Tabet et al. 2010) . To mimic acute inflammation, a nonocclusive collar was placed around the carotid artery in rabbits following infusion with 5A-phospholipid. Treatment with 5A-phospholipid significantly reduced the expression of proinflammatory endothelial adhesion molecules and neutrophil infiltration compared to placebo, and this effect of 5A infusion was similar to the effect observed after infusing lipid-free apoA-I or recombinant HDL. In the same rabbit model, it was shown that 5A-phospholipid reduced the production of radical oxygen species (ROS), such as O 2 À (Tabet et al. 2010 ). The ability of 5A-phospholipid to inhibit the formation of atherosclerosis in vivo has been demonstrated in apolipoprotein E (apoE) knockout mice. Treatment with 30 mg/kg of intravenous 5A-phospholipid three times per week for 13 weeks resulted in 30 % reduction in aortic plaque area in both young apoE knockout mice and older apoE knockout mice with established lesions. The efficiency of the complex to inhibit plaque formation was shown to be dependent on the constitution of the phospholipid component. Reconstituting 5A with a sphingomyelincontaining combination of phospholipids enhanced its anti-atherosclerotic properties. When apoE knockout mice were treated with this complex using the same dosing regimen as used in the previously described experiments, there was a superior 54 % reduction in aortic lesions compared to controls.
In addition to its potent anti-atherosclerotic effects, 5A has been shown to reduce airway inflammation in murine models of asthma (Yao et al. 2011) . Thus, the therapeutic potential of 5A extends beyond atherosclerotic cardiovascular disease.
As of yet, 5A has not been tested in humans. However, the first clinical trial is planned in the near future.
ATI-5261
Bielicki et al. developed ATI-5261, a peptide consisting of 36 amino acids forming a single amphipathic helix with high aqueous solubility that induced ABCA1-mediated cholesterol efflux with similar efficiency as apoA-I (Bielicki et al. 2010) . LDL-R knockout mice received a high-fat Western diet for 13 weeks while concomitantly receiving daily intraperitoneal injections of ATI-5261 during the last 6 weeks. In another model, ApoE knockout mice received a Western diet for 18 weeks, followed by a chow diet with concomitant intraperitoneal injections of ATI-5261 every other day for another 6 weeks. The aortic lesion area and plaque lipid content were significantly reduced in mice treated ATI-5261 compared to mice receiving placebo. The decrease in atherosclerosis was accompanied by increased fecal sterol excretion, which is indicative of increased RCT upon ATI-5261 treatment.
ETC-642
ETC-642 is a complex of a 22-amino acid peptide that forms an amphipathic helix and phospholipids. The complex has been shown to exert multiple favorable effects on LDL and HDL particles (Di Bartolo et al. 2011b) . Following 12 weeks of treatment in rabbits, a shift in LDL subfractions toward less negatively charged particles was observed, indicating a reduction in proinflammatory oxidized LDL. Moreover, a reduction in the particularly atherogenic small dense LDL (sdLDL) subfraction was noticed. Shortly after infusion of ETC-642, there was also a shift in HDL subfractions toward the antiatherogenic pre-β fraction. Moreover, ETC-642 was shown to be a potent inducer of cholesterol efflux from human macrophages in in vitro assays. It has also been shown in vivo to increase the cholesterol content in the HDL fraction, which may indicate increased reverse cholesterol transport (Di Bartolo et al. 2011a; Iwata et al. 2011) . The anti-inflammatory effects of ETC-642 have been demonstrated in rabbit models of acute and chronic inflammation (Di Bartolo et al. 2011a, b) . ETC-642 reduced endothelial adhesion molecule expression both in collared carotid arteries and in the aorta of cholesterol-fed rabbits, and this reduction was similar to effect observed in animals treated with reconstituted HDL. ETC-642 has been shown to induce an anti-inflammatory effect, as HDL isolated from ETC-642-treated rabbits decreased TNF-α-induced expression of NF-kB and endothelial adhesion molecules in human coronary artery endothelial cells (HCAECs) (Di Bartolo et al. 2011b ). In addition, ETC-642 inhibited TNF-α-induced monocyte adhesion in HCAECs (Di Bartolo et al. 2011a ). The efficiency of ETC-642 as an anti-atherosclerotic agent has been demonstrated using intravascular ultrasound (IVUS) in hyperlipidemic rabbits that were treated with either low or high dose (15 or 50 mg/kg, respectively) or placebo two times per week for 12 weeks. Treatment with high-dose ETC-642 significantly inhibited plaque formation compared to controls (Iwata et al. 2011) . 
ApoA-I-Based Infusion Therapy
Lipid-poor pre-β HDL is the main acceptor of cholesterol from peripheral cells, including macrophages in the subendothelial vessel wall, by means of the interaction between apoA-I and the ABCA1 (Kontush and Chapman 2006) . Largely based on the findings that apoA-I overexpression and apoA-I infusion in animal models do inhibit plaque formation, it is anticipated that infusion of apoA-I-containing particles, such as lipid-poor pre-β HDL, has direct beneficial effects on atherosclerosis.
HDL-VHDL Infusions
The atheroprotective effect of infusions of apoA-I-containing particles was first shown in the 1980s by Badimon et al. Cholesterol-fed rabbits were treated with 8 weekly infusions of homologous high-density lipoprotein-very high-density lipoprotein (HDL-VHDL) obtained by ultracentrifugation. Following the 8-week treatment period, a significant reduction in the aortic surface area covered by atherosclerotic-like lipid-rich lesions was found in HDL-VHDL-treated animals, compared to controls (37.9 % vs. 14.9 %). The reduced formation of aortic lesions was accompanied by a reduced total lipid deposition in the vascular wall and liver, whereas no significant differences in plasma lipid profiles were noted between both groups (Badimon et al. 1989) . It was subsequently shown that HDL-VHDL infusions did not only inhibit plaque formation, but also reduced the extent of preexisting lesions in a model where rabbits were fed an atherogenic diet for 60 days to induce atherosclerotic lesions (group 1). Two groups were treated with an additional 30 days of cholesterol-rich diet, with or without weekly HDL-VHDL infusions during the last 30 days (groups 2 and 3). Treatment with HDL-VHDL significantly reduced the aortic surface area covered by fatty streaks (17.8 % in treated rabbits vs. 34 and 38.8 % in control groups) as well as aortic lipid accumulation (Badimon et al. 1990 ).
Purified ApoA-I Infusions
The initial studies performed by Badimon et al. showed that infusions of HDL-VHDL did result in protection against atherosclerosis. Miyazaki et al. subsequently tested the hypothesis that infusions of purified apoA-I would have similar effects. In their first experiment, rabbits were fed an atherogenic diet for 90 days. During the last 30 days, half of the rabbits received weekly injections of purified apoA-I. Treatment with purified apoA-I resulted in a significant reduction in the proportion of the aortic surface area covered by fatty streaks, to a similar extent to treatment with HDL-VHDL (46.0 % vs. 23.9 %). In a second experiment, Miyazaki et al. studied whether purified apoA-I infusions induced regression of established plaques. Rabbits were fed an atherogenic diet for 105 days. Group 1 was sacrificed on day 105. Groups 2, 3, and 4 were fed a chow diet for an additional 60 days. Group 3 received infusions of purified apoA-I every other day, and group 4 received weekly infusions of a higher dose, while rabbits in group 2 served as untreated controls. The aortic surface area covered by atherosclerotic lesions progressed from day 105 to day 165 despite chow diet (50.0 % vs. 86.2 % for groups 1 and 2, respectively). Compared to the controls in group 2, both groups 3 and 4 showed less aortic surface area covered by atherosclerosis (86.2 % vs. 70.2 % and 65.7 %, respectively). However, apoA-I infusions did not induce plaque regression (Miyazaki et al. 1995) .
ApoA-I Milano Infusions
Carriers of the apoA-I Milano mutation are characterized by reduced levels of HDL-C without the anticipated increased risk of CVD (Franceschini et al. 1980 ). Compared to native apoA-I, apoA-I Milano has been shown to induce more ABCA1-mediated cholesterol efflux, and, in addition, apoA-I Milano has been shown to exert superior anti-inflammatory and plaque stabilizing properties (Ibanez et al. 2012) . Ameli et al. showed that infusion of recombinant apoA-I Milano effectively reduced the formation of intimal lesions in cholesterol-fed rabbits following balloon-induced vascular injury. Twenty rabbits on an atherogenic diet underwent balloon injury of the femoral and iliac arteries. Eight animals received injections with a complex of apoA-I Milano and phospholipids on alternating days during a 10-day period, starting 5 days prior to the balloon injury. Eight other animals received only the phospholipid carrier, and 4 animals served as controls; they did not receive any treatment.
Infusions of apoA-I Milano were found to significantly inhibit intimal thickening following balloon injury (0.49 mm 2 vs. 1.14 mm 2 and 1.69 mm 2 ) and to reduce intimal macrophage content. This effect was present while plasma cholesterol levels remained similar among the groups (Ameli et al. 1994) . Subsequent animal studies have confirmed the ability of infusion of recombinant apoA-I Milano to inhibit plaque progression and reduce plaque area of established lesions in models of arterial injury and in apoE-deficient mice (Chiesa et al. 2002; Shah et al. 1998 Shah et al. , 2001 Soma et al. 1995) . A reduction in plaque lipid and macrophage content has been demonstrated after only 48 h of a single infusion (Shah et al. 2001) .
In the "ApoA-I Milano Trial," 57 patients with an acute coronary syndrome (ACS) were randomized to 5 weekly infusions of either a high (45 mg/kg) or a low dose (15 mg/kg) of a complex of recombinant apoA-I Milano with phospholipid carriers (ETC-216) or placebo, and the treatment began within 2 weeks after ACS. Percentage and total atheroma volume and plaque thickness were significantly reduced in patients treated with apoA-I Milano compared to baseline as assessed by IVUS. The infusions with ETC-216 were generally well tolerated. The small pilot study lacked power to detect dose effects and differences between the treatment and placebo groups (Nissen et al. 2003) . Additional analysis revealed that treatment with apoA-I Milano had a beneficial effect on arterial wall remodeling (Nicholls et al. 2006 ). In conclusion, regression of atherosclerosis was demonstrated following short-term infusions, and the results of larger studies with longer follow-up and clinically relevant end points are eagerly awaited.
CSL-111 and CSL-112 Infusions
Two subsequent studies investigated the safety and efficacy of infusion of reconstituted HDL (rHDL), consisting of native apoA-I and phospholipids, on coronary atherosclerosis. CSL-111 is composed of human apoA-I and soybean phosphatidylcholine and thereby resembles native HDL. In the "Effect of rHDL on Atherosclerosis-Safety and Efficacy" (ERASE) trial, a total of 183 patients was randomized to 4 weekly infusions of either 40 or 80 mg/kg of CSL-111 or placebo, and this treatment was started within 2 weeks after an ACS. An IVUS and a quantitative coronary angiography were obtained prior to randomization and 2 weeks after the last infusion. Administration of high-dose CSL-111 was associated with a high incidence of transaminase elevations, which led to early discontinuation of the 80 mg/kg study arm. Treatment with 4 weekly infusions of 40 mg/kg of CSL-111 significantly reduced atheroma volume compared to baseline, to a similar extent as seen in the ApoA-I Milano Trial. However, the differences in atheroma volume between the study groups did not reach statistical significance. Nonetheless, the authors conclude that CSL-111 may exert a favorable treatment effect, as treatment improved plaque characterization index on IVUS and coronary score on quantitative angiography (Tardif et al. 2007 ).
Further development of CSL-111 was discontinued after the observation that the therapy induced a high incidence of liver function abnormalities, possibly related to the high cholate content of the CSL-111 particle.
CSL-112, a second-generation compound with no liver toxicity (Krause and Remaley 2013) , has been tested in two phase 1 studies comprising a total of 93 healthy individuals. In the single-dose study, subjects received doses of up to 135 mg/kg, and in the multiple-dose study, 36 subjects were divided into four groups. Groups 1 and 2 received 4 weekly infusions of either low-or high-dose CSL-112, group 3 received a low dose of CSL-112 twice weekly for 4 weeks, and group 4 received placebo. Infusion of CSL-112 resulted in a dose-dependent increase in apoA-I, which remained above baseline levels for 3 days. A rapid 36-fold increase in pre-β HDL levels was noted, which was accompanied by increased ABCA1-mediated cholesterol efflux (maximum increase 270 % compared to baseline). Importantly, CSL-112 did not cause clinically relevant elevations of liver function parameters (Easton et al. 2013) . A phase 2a study of CSL-112 in patients with stable CVD was recently completed, and the results are eagerly awaited.
CER-001 Infusions
CER-001, an engineered rHDL particle comprising recombinant human wild-type apoA-I and diphosphatidylglycerol and sphingomyelin, was designed to mimic nascent pre-β HDL. CER-001 infusions were shown to reduce atherosclerotic plaque size and aortic macrophage and lipid content in atherosclerosis-prone mice (Goffinet et al. 2012) . A phase 1 randomized crossover study evaluated dose ranges from 0.25 to 45 mg/kg in 32 dyslipidemic volunteers. CER-001 infusions were well tolerated and did not show any safety issue at any dose; in particular there were no liver enzyme elevations. Following administration of a single infusion of low doses of CER-001, plasma total cholesterol and cholesterol in the HDL fraction were significantly elevated (almost 700 % increase in the HDL fraction at the 45 mg/kg dose), which may indicate mobilization of cholesterol from peripheral tissues (Keyserling et al. 2011) . Cholesterol esterification was also observed, consistent with LCAT activation. Three phase 2 trials are currently investigating the effects of CER-001 on atherosclerotic plaques. The "Can HDL Infusions Significantly Quicken Atherosclerosis Regression" (CHI-SQUARE) trial is designed to investigate whether CER-001 infusions induce plaque regression in patients with ACS. In total, 507 patients have been randomized to 6 weekly infusions of three ascending doses of CER-001, or placebo. The primary outcome measure is the absolute change in plaque volume, as determined by IVUS, from baseline to 3 weeks after the last infusion (NCT01201837). In parallel, two openlabel trials are currently evaluating the effects of CER-001 on plaque volume. In the Modifying Orphan Disease Evaluation (MODE) trial (NCT01412034), a total of 23 patients with homozygous familial hypercholesterolemia (FH) is treated for 6 months with biweekly infusions with CER-001. The primary outcome measure in this trial is the percent change in carotid mean vessel wall area as assessed by 3Tesla MRI. A similar regimen is followed in the investigator-driven SAMBA trial, conducted in patients with very low or absent HDL due to genetic defects-familial primary hypoalphalipoproteinemia (FPHA) (EudraCT number 2011-006188-23). Preliminary results presented at the 2013 PACE Snapshot session (ESC, Amsterdam) indicate that CER-001 increases RCT and may effectively reduce aortic atheroma volume.
These studies will provide valuable information about the clinical utility of CER-001 infusions in patients at increased CVD risk.
3.6
Modified ApoA-I
The rapid renal clearance of lipid-poor apoA-I may limit the therapeutic potential of apoA-I-based therapies. TripA-I represents a trimeric apoA-I analogue that functionally resembles wild-type apoA-I, with a prolonged half-life in plasma due to its increased size (Graversen et al. 2008; Ohnsorg et al. 2011) . Intravenous treatment with tripA-I decreased the progression of atherosclerotic lesion size in LDL-R knockout mice on an atherogenic diet, although tripA-I did not affect aortic atherosclerotic lesion size in uremic apoE knockout mice (Graversen et al. 2008; Pedersen et al. 2009 ).
Selective Delipidation
Given that cholesterol-poor HDL particles are particularly effective in inducing reverse cholesterol transport, a procedure has been developed that selectively delipidates large, cholesterol-rich HDL particles, thereby creating small, lipidpoor HDL particles similar to small α-and pre-β-like HDL (HDL selectively delipidated or HDL-sdl). The technique involves mixing plasma with two delipidation reagents, followed by bulk separation by gravity and subsequent passage through a charcoal column to remove residual reagents (Sacks et al. 2009 ). Potential benefits of this technique are the fact that autologous particles are reinfused, which is anticipated to limit potential toxicity, and that the reinfused pre-β HDL particles are deemed particularly effective in promoting cholesterol efflux. Sacks et al. showed that 12 weekly infusions of selectively delipidated HDL reduced diet-induced atherosclerosis in monkeys, as assessed using IVUS. Delipidated small HDL particles were entirely converted into large α-HDL particles after infusion. Combined with the finding that selectively delipidated plasma induced a seven-fold increase in ABCA1-mediated cholesterol efflux, this may indicate enhanced reverse cholesterol transport (Sacks et al. 2009 ). Waksman et al. subsequently randomized 28 patients undergoing cardiac catheterization for ACS to 7 weekly infusions with either selectively delipidated HDL or control plasma to evaluate the safety of the Lipid Sciences Plasma Delipidation System-2 (LS PDS-2) and to explore the potential effects on atheroma volume. The treatment was well tolerated by all patients. On average, there was a 28-fold increase in pre-β-like HDL following delipidation compared to baseline. IVUS was obtained during cardiac catheterization for the ACS and after 2 weeks of the last treatment. A trend toward regression of total atheroma volume was found in patients treated with selective delipidation, while a small increase in atheroma volume was observed in the control group. Although the sample size was too small to detect significant effects on atheroma volume, the trend toward plaque regression can be considered as a beneficial effect. Additional studies in larger cohorts of patients will provide a more definite answer to the question whether delipidation is a potential benefit for patients suffering from an ACS (Waksman et al. 2010 ).
Conclusion
The development of apoA-I analogues has been driven by the observation that apoA-I plays a pivotal role in the antiatherogenic capacity of HDL particles. A large number of apoA-I analogue proteins have been studied in vitro and some did show beneficial effects. However, "the proof of the pudding will be in the eating:" well-designed clinical trials in patients are indispensable to address the role of apoA-I mimetics and alike in atherosclerosis regression.
The clinical potential of rHDL particles reaches beyond the treatment of atherosclerosis. For example, rHDL particles labeled with contrast-generating agents, such as gadolinium or 125 I, can be used as natural nanoparticles in medical imaging to visualize natural targets such as macrophages in atherosclerotic plaques or other targets by attaching targeting molecules (Ryan 2010; Stanley 2014 ). In addition, rHDL can be used as a vector for drug transport by incorporating lipophilic drugs into rHDL particles, which may decrease drug toxicity and increase bioavailability (Stanley 2014) .
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